CryptoQuant CEO Ki Young Ju expects “boring sideways” trading through Q1 2026 as capital rotates to equities and metals. Strategy raised $1.25B and bought Bitcoin directly as ETF outflows hit $486M on ...

NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a ...

Multiple factors, including ETF outflows, contracting demand, and price falling below key support levels, indicate the start of a BTC bear market. Bitcoin (BTC) demand growth has slowed significantly ...

Micron announced it will phase out its Crucial brand's consumer memory and SSD products by February 2026, marking its exit from the nearly 30-year-old consumer market. This move reflects the ...

EAST PALESTINE — With the property damage payments expected to begin in early 2026 now that the appeals of the final approval of the $600 million settlement between class members and Norfolk Southern ...

ORCHARD PARK — The Buffalo Bills swapped one No. 18 for another. It might foreshadow changes coming to the passing game. Roughly 90 minutes after the Bills announced they released wide receiver Elijah ...

The second phase of the Chambersburg Signal Improvement Project is updating 63 traffic signals in the area. Updates include responsive signal timing, flashing yellow turn arrows, and new green turn ...

Bone-colored bluffs and jagged cliffs line the Monterey shoreline where chalky sand meets redwoods. Its rugged coastline, including beloved destinations such as Big Sur, is well-known California ...

WASHINGTON, DC: U.S. President Donald Trump is joined by (L-R) U.S. Secretary of Commerce Howard Lutnick, U.S. Vice President JD Vance, Director of Medicare and Deputy Administrator of CMS Chris Klomp ...

Target’s corporate culture, once known for flexibility and collaboration, is starting to show cracks, with employees describing a workplace increasingly defined by uncertainty, poor communication and ...

Daiichi Sankyo and Merck & Co. have reported midphase ovarian cancer data, clearing the partners to advance the antibody-drug conjugate into the phase 3 part of the trial. The phase 2 trial tested ...